Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Review
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
11,683 | Dovepress* | 10,286+ | 1,694 | 11,980 | |
PubMed Central* | 1,397 | 490 | 1,887 | ||
Totals | 11,683 | 2,184 | 13,867 | ||
*Since 16 October 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
30 | 1 | 0 | 0 | 14 | 15 |
View citations on PubMed Central and Google Scholar